Submit Your Hematology and Oncology Research
Join leading researchers advancing our understanding of blood disorders, hematologic malignancies, and cancer biology through rigorous peer-reviewed publication
Start Your Submission NowTwo Convenient Submission Methods
We offer two streamlined pathways for manuscript submission, designed to accommodate your preferences and workflow. Choose the method that works best for your research submission needs.
ManuscriptZone Portal
Our comprehensive manuscript management system provides complete control over your submission from start to publication. Ideal for researchers who value real-time tracking and direct communication with editors.
- Auto-save functionality protects your work
- Guided step-by-step submission workflow
- Real-time manuscript status tracking
- Direct access to reviewer comments
- Revision management tools
- Secure document upload and storage
Best for: Complete manuscript management, tracking revisions, and ongoing communication with editorial team
Submit via ManuscriptZoneQuick Submission Form
A streamlined submission process for straightforward manuscripts. Perfect for researchers who prefer a simple, fast submission without account creation.
- No account registration required
- Simple one-page submission form
- Fast manuscript upload process
- Immediate submission confirmation
- Email-based status updates
- Minimal steps to complete
Best for: Quick submissions, first-time authors, and straightforward manuscript types
Use Quick Submission FormArticle Types We Accept
The Journal of Hematology and Oncology Research publishes diverse research contributions that advance our understanding of blood disorders, hematologic malignancies, and cancer biology. We welcome submissions across the full spectrum of hematology and oncology research, from molecular mechanisms to translational applications.
Original Research Articles
Novel findings in leukemia biology, lymphoma pathogenesis, myeloma mechanisms, or solid tumor hematology. Include experimental studies on disease models, biomarker discovery, and molecular pathway analysis.
Systematic Reviews & Meta-Analyses
Comprehensive evidence synthesis on hematologic malignancies, cancer biomarkers, treatment outcomes, or disease mechanisms. Must follow PRISMA guidelines for systematic reviews.
Clinical Case Reports
Rare presentations of hematologic disorders, unusual cancer manifestations, or novel treatment responses. Must provide educational value and contribute to clinical understanding.
Methods & Protocols
Novel laboratory techniques for hematology research, cancer cell analysis, molecular diagnostics, or experimental protocols. Must be reproducible and provide detailed methodology.
Short Communications
Preliminary findings, novel observations, or rapid reports on emerging topics in hematology and oncology. Ideal for time-sensitive discoveries requiring quick dissemination.
Review Articles
Comprehensive overviews of current knowledge in specific areas of hematology or oncology. Should synthesize recent advances and identify future research directions.
Translational Research
Studies bridging basic hematology/oncology research with clinical applications. Include biomarker validation, therapeutic target identification, or precision medicine approaches.
Clinical Trial Reports
Results from clinical trials in hematologic malignancies or cancer treatment. Must be registered in recognized trial registries and follow CONSORT guidelines.
Research Topics We Prioritize:
- Molecular mechanisms of leukemia, lymphoma, and myeloma pathogenesis
- Novel biomarkers for hematologic malignancy diagnosis and prognosis
- Cancer immunotherapy and immune checkpoint mechanisms
- Hematopoietic stem cell biology and transplantation research
- Precision oncology approaches and targeted therapy development
- Tumor microenvironment interactions in blood cancers
- Drug resistance mechanisms in hematologic malignancies
- Molecular profiling and genomic characterization of cancers
- Novel therapeutic targets in oncology and hematology
- Translational studies bridging bench research to clinical application
Pre-Submission Checklist
Before submitting your manuscript, ensure you have completed all necessary preparations. This checklist helps guarantee a smooth submission process and faster editorial review.
Manuscript Preparation
- Manuscript formatted according to journal guidelines (Word or LaTeX format accepted)
- Abstract clearly states objectives, methods, results, and conclusions (250-300 words)
- Keywords selected from MeSH terms or relevant hematology/oncology terminology (4-6 keywords)
- All figures prepared in high resolution (TIFF or EPS format, minimum 300 DPI)
- Tables formatted properly with clear headers and legends
- References formatted in journal style (Vancouver or AMA format preferred)
- Supplementary materials prepared if applicable
Ethical Requirements
- Ethics approval obtained for human subject research (IRB approval letter required)
- Informed consent documented for clinical studies and case reports
- Animal research complies with ARRIVE guidelines (IACUC approval required)
- Clinical trials registered in recognized database (ClinicalTrials.gov, etc.)
- Competing interests declared for all authors
- Funding sources clearly stated
- Data availability statement included
Author Information
- All authors have approved the final manuscript version
- Author contributions clearly defined (using CRediT taxonomy recommended)
- Corresponding author contact information complete and accurate
- ORCID iDs provided for all authors (strongly recommended)
- Institutional affiliations current and complete
First-time submitting to an open access journal? Our editorial team is here to guide you through the process. We provide detailed feedback at every stage and work with authors to ensure their research meets publication standards.
Peer Review Timeline
We are committed to providing efficient, rigorous peer review while maintaining the highest standards of scientific integrity. Our transparent timeline helps you plan your publication strategy.
Manuscript Submission
Submit your manuscript through ManuscriptZone or Quick Submission Form. You will receive immediate confirmation with a unique manuscript ID for tracking.
Day 0Editorial Screening
Our editors assess manuscript scope, quality, and fit with journal aims. We check for completeness, ethical compliance, and adherence to submission guidelines.
3 daysPeer Review Assignment
Manuscripts are sent to expert reviewers specializing in hematology, oncology, or your specific research area. We select reviewers based on expertise and publication record.
5 daysExpert Review Process
Reviewers evaluate scientific rigor, methodology, data interpretation, and contribution to the field. We use single-blind peer review to ensure objectivity.
21 daysEditorial Decision
Based on reviewer feedback, editors make a decision: Accept, Minor Revision, Major Revision, or Reject. Detailed reviewer comments are provided to guide revisions.
28 days totalRevision & Resubmission
Authors revise manuscript based on reviewer feedback. Revised manuscripts receive priority re-review by the same reviewers when possible.
Author timeline variesRe-review Process
Reviewers assess whether revisions adequately address their concerns. This stage is typically faster than initial review.
14 daysFinal Acceptance
Once all reviewer concerns are addressed, manuscript is formally accepted for publication. Authors receive acceptance letter and publication agreement.
1-2 daysProduction & Publication
Manuscript undergoes copyediting, typesetting, and final author proofing. Published online with immediate open access and DOI assignment.
10 daysAverage time from submission to publication: 60 days (including author revision time). We prioritize timely publication while maintaining rigorous peer review standards.
Submission Guidelines Summary
Following these guidelines ensures efficient processing of your manuscript and helps avoid delays in the review process.
Manuscript Format
Submit manuscripts in Microsoft Word (.doc, .docx) or LaTeX format. PDF submissions are accepted for initial review but final versions must be in editable format. Use standard fonts (Times New Roman, Arial, or Calibri) with 12-point font size, double-spacing, and 1-inch margins on all sides.
Structure Requirements
Original research articles should follow the standard IMRAD structure: Introduction, Methods, Results, and Discussion. Include a structured abstract (Background, Methods, Results, Conclusions) of 250-300 words. Provide 4-6 keywords using MeSH terms or relevant hematology/oncology terminology.
Figure and Table Guidelines
Submit figures as separate files in TIFF or EPS format with minimum 300 DPI resolution. Color figures are encouraged for online publication. Tables should be editable (not images) and include clear headers and legends. Number all figures and tables consecutively and cite them in the text.
Reference Style
Use Vancouver or AMA citation style with numbered references in order of appearance. Include all authors for references with up to 6 authors; for 7 or more authors, list the first 3 followed by "et al." Verify all references are accurate and complete.
Ethical Requirements
Human subject research requires IRB approval and informed consent documentation. Animal studies must comply with ARRIVE guidelines and include IACUC approval. Clinical trials must be registered in recognized databases (ClinicalTrials.gov, ISRCTN, etc.). Declare all competing interests and funding sources.
Data Availability
Include a data availability statement describing where readers can access the data supporting your findings. We encourage deposition of datasets in recognized repositories (GenBank, GEO, ProteomeXchange, etc.) and sharing of research materials when possible.
Need detailed formatting guidelines? Visit our Instructions for Authors page for comprehensive submission requirements, or contact our editorial team for clarification on specific questions.
Need Assistance?
Our editorial team is here to support you throughout the submission and publication process. Whether you have questions about manuscript preparation, submission procedures, or publication policies, we're ready to help.
Contact us at: [email protected]
